[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised …
K Park, EH Tan, K O'Byrne, L Zhang, M Boyer… - The Lancet …, 2016 - thelancet.com
Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6) …
Background Afatinib—an oral irreversible ErbB family blocker—improves progression-free
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
survival compared with pemetrexed and cisplatin for first-line treatment of patients with …
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JCH Yang, LV Sequist, SL Geater, CM Tsai… - The lancet …, 2015 - thelancet.com
Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
[HTML][HTML] Meta-analysis of first-line therapies in advanced non–small-cell lung cancer harboring EGFR-activating mutations
Introduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …
[HTML][HTML] Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX …
Background Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive
non-small-cell lung cancer (NSCLC). In the case of drug-related grade≥ 3 or selected …
non-small-cell lung cancer (NSCLC). In the case of drug-related grade≥ 3 or selected …
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
Introduction Previously, we developed a database of 693 patients with NSCLC and
uncommon EGFR mutations treated with afatinib. Here, we provide an update of> 1000 …
uncommon EGFR mutations treated with afatinib. Here, we provide an update of> 1000 …
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of …
T Kato, H Yoshioka, I Okamoto, A Yokoyama… - Cancer …, 2015 - Wiley Online Library
In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma patients and overall …
[HTML][HTML] Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: subgroup analyses of the LUX-Lung 3, LUX-Lung 6 …
Background Afatinib is approved in the US, Europe, and several other regions for first-line
treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell …
treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell …
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non–small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both
N Katakami, S Atagi, K Goto, T Hida, T Horai… - Journal of Clinical …, 2013 - ascopubs.org
Purpose New molecular targeted agents are needed for patients with non–small-cell lung
cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral …
cancer (NSCLC) who progress while receiving erlotinib, gefitinib, or both. Afatinib, an oral …
相关搜索
- lux lung afatinib in patients
- lux lung egfr mutations
- lung cancer gefitinib in patients
- egfr mutations japanese patients
- lux lung subgroup analysis
- egfr mutations subgroup analysis
- prior treatment afatinib in patients
- lux lung prior treatment
- lung cancer meta analysis
- safety of afatinib gefitinib or erlotinib
- lux lung dose adjustment
- lung adenocarcinoma efficacy of afatinib
- lux lung safety and efficacy
- lux lung gefitinib in patients
- lung cancer afatinib in patients
- lux lung efficacy of afatinib